Evidence map›Paper›PMID 25270371›Full record

ArticleMolecular neurobiology2015

Degradation of βII-Spectrin Protein by Calpain-2 and Caspase-3 Under Neurotoxic and Traumatic Brain Injury Conditions.

Firas H Kobeissy, Ming Cheng Liu, Zhihui Yang, Zhiqun Zhang, Wenrong Zheng, Olena Glushakova, Stefania Mondello, John Anagli, Ronald L Hayes, Kevin K W Wang

RetractedErratum issuedAbstract readRetracted Publication
In one paragraph

Article in Molecular neurobiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Sex-based differences of antioxidant enzyme nanoparticle effects following traumatic brain injury.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Firas H KobeissyCenter for Neuroproteomics and Biomarkers Research, Department of Psychiatry, University of Florida, Gainesville, FL, 32610, USA, firasko@gmail.com.
Ming Cheng Liu
Zhihui Yang
Zhiqun Zhang
Wenrong Zheng
Olena Glushakova
Stefania Mondello
John Anagli
Ronald L Hayes
Kevin K W Wang
University of Florida · USBanyan Biomarkers (United States) · USAmerican University of Beirut · LBUniversity of Messina · IT

Funding

Biochemical Markers of Traumatic Brain InjuryR01NS052831 · NINDS · UNIVERSITY OF FLORIDA · PI ROBICSEK, STEVEN ANDREW · 2006 to 2010
$4.9M
Biochemical Basis of Axonal & Myelin Injury In Head TraumaR01NS049175 · NINDS · UNIVERSITY OF FLORIDA · PI WANG, KEVIN KA WANG · 2005 to 2008
$1.9M
NINDS NIH HHS R01 NS049175-01NINDS NIH HHS R01 NS052831NINDS NIH HHS R01 NS052831-01
6 · The paper itself

Abstract

A major consequence of traumatic brain injury (TBI) is the rapid proteolytic degradation of structural cytoskeletal proteins. This process is largely reflected by the interruption of axonal transport as a result of extensive axonal injury leading to neuronal cell injury. Previous work from our group has described the extensive degradation of the axonally enriched cytoskeletal αII-spectrin protein which results in molecular signature breakdown products (BDPs) indicative of injury mechanisms and to specific protease activation both in vitro and in vivo. In the current study, we investigated the integrity of βII-spectrin protein and its proteolytic profile both in primary rat cerebrocortical cell culture under apoptotic, necrotic, and excitotoxic challenge and extended to in vivo rat model of experimental TBI (controlled cortical impact model). Interestingly, our results revealed that the intact 260-kDa βII-spectrin is degraded into major fragments (βII-spectrin breakdown products (βsBDPs)) of 110, 108, 85, and 80 kDa in rat brain (hippocampus and cortex) 48 h post-injury. These βsBDP profiles were further characterized and compared to an in vitro βII-spectrin fragmentation pattern of naive rat cortex lysate digested by calpain-2 and caspase-3. Results revealed that βII-spectrin was degraded into major fragments of 110/85 kDa by calpain-2 activation and 108/80 kDa by caspase-3 activation. These data strongly support the hypothesis that in vivo activation of multiple protease system induces structural protein proteolysis involving βII-spectrin proteolysis via a specific calpain and/or caspase-mediated pathway resulting in a signature, protease-specific βsBDPs that are dependent upon the type of neural injury mechanism. This work extends on previous published work that discusses the interplay spectrin family (αII-spectrin and βII-spectrin) and their susceptibility to protease proteolysis and their implication to neuronal cell death mechanisms.

Indexed as

ProteolysisAnimalsApoptosisBrain InjuriesCalpainCaspase 3Cells, CulturedCerebral CortexHippocampusHumansImmunoblottingMaleNecrosisNeurotoxicity SyndromesNeurotoxinsProtease InhibitorsCalpainCaspase 3NeurotoxinsProtease InhibitorsSpectrin

Identifiers

PMID25270371
PMCPMC4383741
OpenAlexW2054724790

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.